Susceptibility to COPD: Differential proteomic profiling after acute smoking

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Franciosi, Lorenza ^a   Postma, Dirkje S ^b   Van Den Berge, Maarten ^b   Govorukhina, Natalia ^a   Horvatovich, Peter L ^a   Fusetti, Fabrizia ^a   Poolman, Bert ^a   Lodewijk, Monique E ^b   Timens, Wim ^b   Bischoff, Rainer ^a   Ten Hacken, Nick H T ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 3A1; CALGRANULIN A; CALGRANULIN B; PEROXIREDOXIN 1; PROTEIN SERPINB3; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; UTEROGLOBIN;

ADULT; AGED; ARTICLE; BODY FLUID; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL LINING FLUID; FAMILY HISTORY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; LUNG ALVEOLUS EPITHELIUM; MALE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEOMICS; SMOKING; ADOLESCENT; ADVERSE EFFECTS; EPITHELIUM; METABOLISM; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; DISEASE SUSCEPTIBILITY; EPITHELIUM; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEOMICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; TIME FACTORS; YOUNG ADULT;

EID: 84904539248     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102037     Document Type: Article

References (46)

1. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, et al. (1995) Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 8: 1398-1420.
2. Sabroe I, Parker LC, Calverley PM, Dower SK, Whyte MK (2007) Pathological networking: a new approach to understanding COPD. Thorax 62: 733-738. (Pubitemid 47235020)
3. O'Neil SE, Lundback B, Lotvall J (2011) Proteomics in asthma and COPD phenotypes and endotypes for biomarker discovery and improved understanding of disease entities. J Proteomics 75: 192-201. S1874-3919(11)00494-5 [pii];10.1016/j.jprot.2011.10.008 [doi].
4. Chen H, Wang D, Bai C, Wang X (2010) Proteomics-based biomarkers in chronic obstructive pulmonary disease. J Proteome Res 9: 2798-2808. 10.1021/pr100063r [doi].
5. Nicholas BL, O'Connor CD, Djukanovic R (2009) From proteomics to prescription-the search for COPD biomarkers. COPD 6: 298-303. 10.1080/15412550903049140 [pii].
6. Plymoth A, Lofdahl CG, Ekberg-Jansson A, Dahlback M, Broberg P, et al. (2007) Protein expression patterns associated with progression of chronic obstructive pulmonary disease in bronchoalveolar lavage of smokers. Clin Chem 53: 636-644. clinchem.2006.076075 [pii];10.1373/clinchem.2006.076075 [doi].
7. Plymoth A, Yang Z, Lofdahl CG, Ekberg-Jansson A, Dahlback M, et al. (2006) Rapid proteome analysis of bronchoalveolar lavage samples of lifelong smokers and never-smokers by micro-scale liquid chromatography and mass spectrometry. Clin Chem 52: 671-679. clinchem.2005.060715 [pii];10.1373/ clinchem.2005.060715 [doi].
8. Tu C, Mammen MJ, Li J, Shen X, Jiang X, et al. (2014) Large-scale, ion-current-based proteomics investigation of bronchoalveolar lavage fluid in chronic obstructive pulmonary disease patients. J Proteome Res 13: 627-639. 10.1021/pr4007602 [doi].
9. Pastor MD, Nogal A, Molina-Pinelo S, Melendez R, Romero-Romero B, et al. (2013) Identification of oxidative stress related proteins as biomarkers for lung cancer and chronic obstructive pulmonary disease in bronchoalveolar lavage. Int J Mol Sci 14: 3440-3455. ijms14023440 [pii];10.3390/ijms14023440 [doi].
10. Gray RD, MacGregor G, Noble D, Imrie M, Dewar M, et al. (2008) Sputum proteomics in inflammatory and suppurative respiratory diseases. Am J Respir Crit Care Med 178: 444-452. 200703-409OC [pii];10.1164/rccm.200703-409OC [doi].
11. Nicholas B, Skipp P, Mould R, Rennard S, Davies DE, et al. (2006) Shotgun proteomic analysis of human-induced sputum. Proteomics 6: 4390-4401. 10.1002/pmic.200600011 [doi]. (Pubitemid 44277040)
12. Casado B, Iadarola P, Pannell LK, Luisetti M, Corsico A, et al. (2007) Protein expression in sputum of smokers and chronic obstructive pulmonary disease patients: a pilot study by CapLC-ESI-Q-TOF. J Proteome Res 6: 4615-4623. 10.1021/pr070440q [doi].
13. Ohlmeier S, Mazur W, Linja-Aho A, Louhelainen N, Ronty M, et al. (2012) Sputum proteomics identifies elevated PIGR levels in smokers and mild-tomoderate COPD. J Proteome Res 11: 599-608. 10.1021/pr2006395 [doi].
14. Fumagalli M, Ferrari F, Luisetti M, Stolk J, Hiemstra PS, et al. (2012) Profiling the Proteome of Exhaled Breath Condensate in Healthy Smokers and COPD Patients by LC-MS/MS. Int J Mol Sci 13: 13894-13910. ijms131113894 [pii];10.3390/ijms131113894 [doi].
15. Tzortzaki EG, Siafakas NM (2009) A hypothesis for the initiation of COPD. Eur Respir J 34: 310-315.
16. van der Vaart H, Postma DS, Timens W, ten Hacken NH (2004) Acute effects of cigarette smoke on inflammation and oxidative stress: a review. Thorax 59: 713-721. (Pubitemid 39061538)
17. van der Vaart.H, Postma DS, Timens W, Hylkema MN, Willemse BW, et al. (2005) Acute effects of cigarette smoking on inflammation in healthy intermittent smokers. Respir Res 6: 22.
18. Siafakas NM, Tzortzaki EG (2002) Few smokers develop COPD. Why? Respir Med 96: 615-624.
19. Silverman EK, Chapman HA, Drazen JM, Weiss ST, Rosner B, et al. (1998) Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med 157: 1770-1778.
20. Kipnis E, Hansen K, Sawa T, Moriyama K, Zurawel A, et al. (2008) Proteomic analysis of undiluted lung epithelial lining fluid. Chest 134: 338-345. 134/2/338 [pii];10.1378/chest.07-1643 [doi].
21. Lo Tam Loi AT, Hoonhorst SJ, Franciosi L, Bischoff R, Hoffmann RF, et al. (2013) Acute and chronic inflammatory responses induced by smoking in individuals susceptible and non-susceptible to development of COPD: from specific disease phenotyping towards novel therapy. Protocol of a cross-sectional study. BMJ Open 3.
22. Du R, I, Barber PV, Goldring J, Lewis RA, Mandal S, et al. (2011) British Thoracic Society guideline for advanced diagnostic and therapeutic flexible bronchoscopy in adults. Thorax 66 Suppl 3: iii1-21.
23. Franciosi L, Govorukhina N, Ten HN, Postma D, Bischoff R (2011) Proteomics of epithelial lining fluid obtained by bronchoscopic microprobe sampling. Methods Mol Biol 790: 17-28.
24. Choe L, D'Ascenzo M, Relkin NR, Pappin D, Ross P, et al. (2007) 8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease. Proteomics 7: 3651-3660. (Pubitemid 350022271)
25. Steen A, Wiederhold E, Gandhi T, Breitling R, Slotboom DJ (2011) Physiological adaptation of the bacterium Lactococcus lactis in response to the production of human CFTR. Mol Cell Proteomics 10: M000052MCP200.
26. Dijkstra A, Postma DS, Noordhoek JA, Lodewijk ME, Kauffman HF, et al. (2009) Expression of ADAMs ("a disintegrin and metalloprotease") in the human lung. Virchows Arch 454: 441-449.
27. Lunardi F, Villano G, Perissinotto E, Agostini C, Rea F, et al. (2011) Overexpression of SERPIN B3 promotes epithelial proliferation and lung fibrosis in mice. Lab Invest 91: 945-954.
28. de Torre C., Ying SX, Munson PJ, Meduri GU, Suffredini AF (2006) Proteomic analysis of inflammatory biomarkers in bronchoalveolar lavage. Proteomics 6: 3949-3957. (Pubitemid 44081167)
29. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J (2009) The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 86: 557-566.
30. Lorenz E, Muhlebach MS, Tessier PA, Alexis NE, Duncan HR, et al. (2008) Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases. Respir Med 102: 567-573.
31. Lakind JS, Holgate ST, Ownby DR, Mansur AH, Helms PJ, et al. (2007) A critical review of the use of Clara cell secretory protein (CC16) as a biomarker of acute or chronic pulmonary effects. Biomarkers 12: 445-467. (Pubitemid 47304652)
32. Kwon HS, Bae YJ, Moon KA, Lee YS, Lee T, et al. (2012) Hyperoxidized peroxiredoxins in peripheral blood mononuclear cells of asthma patients is associated with asthma severity. Life Sci 90: 502-508.
33. van der TM, Smit-de Vries MP, Slebos DJ, de Bruin HG, Abello N, et al. (2007) Cigarette smoke irreversibly modifies glutathione in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 293: L1156-L1162.
34. Schick C, Pemberton PA, Shi GP, Kamachi Y, Cataltepe S, et al. (1998) Crossclass inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: a kinetic analysis. Biochemistry 37: 5258-5266. (Pubitemid 28176527)
35. Landi C, Bargagli E, Magi B, Prasse A, Muller-Quernheim J, et al. (2011) Proteome analysis of bronchoalveolar lavage in pulmonary langerhans cell histiocytosis. J Clin Bioinforma 1: 31.
36. van Miert E., Dumont X, Bernard A (2005) CC16 as a marker of lung epithelial hyperpermeability in an acute model of rats exposed to mainstream cigarette smoke. Toxicol Lett 159: 115-123. (Pubitemid 41334799)
37. Lumsden AB, McLean A, Lamb D (1984) Goblet and Clara cells of human distal airways: evidence for smoking induced changes in their numbers. Thorax 39: 844-849. (Pubitemid 14022735)
38. Shijubo N, Itoh Y, Yamaguchi T, Shibuya Y, Morita Y, et al. (1997) Serum and BAL Clara cell 10 kDa protein (CC10) levels and CC10-positive bronchiolar cells are decreased in smokers. Eur Respir J 10: 1108-1114. (Pubitemid 27201817)
39. Shijubo N, Honda Y, Itoh Y, Yamaguchi T, Kuroki Y, et al. (1998) BAL surfactant protein A and Clara cell 10-kDa protein levels in healthy subjects. Lung 176: 257-265. (Pubitemid 28252562)
40. Merkel D, Rist W, Seither P, Weith A, Lenter MC (2005) Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface-enhanced laser desorption/ionizationmass spectrometry profiling with mass spectrometric protein identification. Proteomics 5: 2972-2980. (Pubitemid 41059773)
41. Bernard A, Marchandise FX, Depelchin S, Lauwerys R, Sibille Y (1992) Clara cell protein in serum and bronchoalveolar lavage. Eur Respir J 5: 1231-1238. (Pubitemid 23017684)
42. Lomas DA, Silverman EK, Edwards LD, Miller BE, Coxson HO, et al. (2008) Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax 63: 1058-1063.
43. Braido F, Riccio AM, Guerra L, Gamalero C, Zolezzi A, et al. (2007) Clara cell 16 protein in COPD sputum: a marker of small airways damage? Respir Med 101: 2119-2124. (Pubitemid 47324246)
44. Celedon JC, Speizer FE, Drazen JM, Weiss ST, Campbell EJ, et al. (1999) Bronchodilator responsiveness and serum total IgE levels in families of probands with severe early-onset COPD. Eur Respir J 14: 1009-1014.
45. McCloskey SC, Patel BD, Hinchliffe SJ, Reid ED, Wareham NJ, et al. (2001) Siblings of patients with severe chronic obstructive pulmonary disease have a significant risk of airflow obstruction. Am J Respir Crit Care Med 164: 1419-1424. (Pubitemid 33124020)
46. Patel BD, Coxson HO, Pillai SG, Agusti AG, Calverley PM, et al. (2008) Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 178: 500-505.